Genetic amplification of the vascular endothelial growth factor (VEGF) pathway genes, including VEGFA, in human osteosarcoma
Open Access
- 14 April 2011
- Vol. 117 (21), 4925-4938
- https://doi.org/10.1002/cncr.26116
Abstract
BACKGROUND: Osteosarcoma is the most common primary tumor of bone. It is a highly vascular and extremely destructive malignancy that mainly affects children and young adults. The authors conducted microarray‐based comparative genomic hybridization (aCGH) and pathway analyses to gain a systemic view of pathway alterations in the genetically altered genes. METHODS: Recurrent amplified and deleted genes that were detected by aCGH were subjected to an analysis based on the Kyoto Encyclopedia of Genes and Genomes to identify the altered pathways. Among the enriched pathways, vascular endothelial growth factor (VEGF) pathway genes collectively were amplified, and alterations of this pathway were validated by fluorescence in situ hybridization (FISH) and immunohistochemistry analyses in 58 formalin‐fixed, paraffin‐embedded osteosarcoma archival tissues that had clinical follow‐up information. RESULTS: The pathway enrichment analyses of the aCGH data revealed that VEGF pathway genes, including the VEGFA gene itself, were amplified significantly in osteosarcoma. Genetic amplification of the VEGFA gene, both focally and in larger fragment, was validated by FISH analysis. It is noteworthy that amplification of the VEGFA gene and elevated expression of the VEGFA protein were associated significantly with microvascular density and adverse tumor‐free survival in patients with osteosarcoma. CONCLUSIONS: The authors report for the first time that VEGF pathway genes, including the VEGFA gene, are amplified in osteosarcoma. Amplification of the VEGFA gene is not only an important mechanism for elevated VEGFA protein expression but also is a poor prognostic factor for tumor‐free survival. Combined classification of VEGFA gene amplification and positive VEGFA protein expression may provide a more accurate stratification method of selecting anti‐VEGF therapy for patients with osteosarcoma. Cancer 2011;. © 2011 American Cancer Society.Keywords
This publication has 38 references indexed in Scilit:
- LSAMP, a novel candidate tumor suppressor gene in human osteosarcomas, identified by array comparative genomic hybridizationGenes, Chromosomes and Cancer, 2009
- Guidelines for Human Epidermal Growth Factor Receptor 2 Testing: Biologic and Methodologic ConsiderationsJournal of Clinical Oncology, 2009
- Copy number gains in EGFR and copy number losses in PTEN are common events in osteosarcoma tumorsCancer, 2008
- Hypoxia Markers in Human Osteosarcoma: An Exploratory StudyClinical Orthopaedics and Related Research, 2008
- The endogenous anti-angiogenic VEGF isoform, VEGF165b inhibits human tumour growth in miceBritish Journal of Cancer, 2008
- HIF1α Induces the Recruitment of Bone Marrow-Derived Vascular Modulatory Cells to Regulate Tumor Angiogenesis and InvasionCancer Cell, 2008
- American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast CancerJournal of Clinical Oncology, 2007
- Anti-angiogenic therapy for osteosarcomaCancer and Metastasis Reviews, 2006
- Role of the Vascular Endothelial Growth Factor Pathway in Tumor Growth and AngiogenesisJournal of Clinical Oncology, 2005
- Prognostic Relevance of Increased Angiogenesis in OsteosarcomaClinical Cancer Research, 2004